Clinical Evaluation of the Efficacy of a Dietary Supplement Claiming Anti-aging Properties and UV-protection

NCT ID: NCT06571409

Last Updated: 2025-01-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

99 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-09-25

Study Completion Date

2025-01-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study aims to assess the anti-aging and photoprotective efficacy of two active concentrations of a food supplement composed of Coriander Seed Oil (CSO).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A double blind, parallel groups, placebo-controlled study is carried out on 90 female subjects aged between 35 and 65 years old with visible Crow's feet wrinkles and mild to moderate skin slackness.

The study foresees 56 days of products intake. Evaluations of the parameters under study are performed at baseline, after 14, 28 and 56 days of products consumption.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Coriander Seed Oil - Dose 1

Dietary supplement - Coriander Seed Oil dose 1

Group Type EXPERIMENTAL

Coriander Seed Oil - Dose 1

Intervention Type DIETARY_SUPPLEMENT

The study foresees the intake of 1 capsule per day during 56 days

Coriander Seed Oil - Dose 2

Dietary supplement - Coriander Seed Oil dose 2

Group Type EXPERIMENTAL

Coriander Seed Oil - Dose 2

Intervention Type DIETARY_SUPPLEMENT

The study foresees the intake of 1 capsule per day during 56 days

Placebo

Dietary supplement - Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

The study foresees the intake of 1 capsule per day during 56 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Coriander Seed Oil - Dose 1

The study foresees the intake of 1 capsule per day during 56 days

Intervention Type DIETARY_SUPPLEMENT

Coriander Seed Oil - Dose 2

The study foresees the intake of 1 capsule per day during 56 days

Intervention Type DIETARY_SUPPLEMENT

Placebo

The study foresees the intake of 1 capsule per day during 56 days

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy female subjects
* Caucasian ethnicity
* Age between 35 and 65 years old (extremes included)
* Phototype I to III (with all skin types without any specific repartition)
* Visible Crow's feet wrinkles (\> 2 according to Skin Aging Atlas - Caucasian Type - Bazin Roland) and mild to moderate skin slackness at cheek level (grade 1-3 - internal clinical scale)
* Subjects who have not been recently involved in any other similar study (at least 1 month of wash-out)
* Subjects registered with health social security or health social insurance
* Subjects having signed the Informed Consent Form (ICF) and Privacy Policy for their participation in the study and a photograph authorization
* Subjects able to understand the language used in the investigation center and the information given
* Subjects able to comply with the protocol and follow protocol constraints and specific requirements
* Willingness to use during all the study period only the product to be tested
* Willingness not to use similar products that could interfere with the expected product effect to be tested (e.g. with antiaging or soothing or UV protection efficacy)
* Willingness to not vary the normal daily routine (i.e. lifestyle, physical activity, diet etc.)
* Subjects under effective contraception (oral/not oral) if women of childbearing potential; not expected to be changed during the trial
* Subjects who have not sun exposure (both natural or artificial) for at least two months
* Subjects who accept not to expose in intensive way to UV rays during the whole study duration
* Subjects who have not been involved in any sun test (for SPF evaluation) or tests that provide skin irradiation since less than two months

Exclusion Criteria

* Subject is taking part or planning to participate to another clinical study in the same or in another investigation center
* Subject who is deprived of freedom by administrative or legal decision or under guardianship
* Subject admitted in a sanitary or social facilities
* Subject who is planning an hospitalization during the study
* Subjects under treatment with food supplements which could interfere with the functionality of the product under study
* Subject breastfeeding, pregnant or not willing to take necessary precautions to avoid pregnancy during the study (if women of childbearing potential)
* Subject has started or changed estrogen-progesterone contraception or hormonal treatment, within the 3 months prior to the study or foreseeing it for the duration of the study
* Subject having an acute, chronic or progressive illness liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements
* Subjects under radiotherapy, chemotherapy at any time
* Subject having a skin condition liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements
* Pharmacological treatments (topic or systemic) known to interfere with skin metabolism/physiology
* Subjects under locally pharmacological/non-pharmacological treatment applied on the skin area monitored during the test
* Subject with known or suspected sensitization to one or more test formulation ingredients
* Subjects considered as not adequate to participate to the study by the investigator
* Adult protected by law (under control or hospitalized in public or private institutions for reasons other than research, or incarcerated)
* Subjects not able to communicate or cooperate with the investigator for problems related to language, mental retardation or impaired brain function
Minimum Eligible Age

35 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Seppic

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Eleonora Spartà

Role: STUDY_DIRECTOR

Complife Italia S.r.l

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Complife Italia S.r.l

San Martino Siccomario, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IT0003160/24

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Centella Asiatica in Older Adults
NCT06472791 NOT_YET_RECRUITING NA